Company: HRTX
Filing Date: 2025-08-12
Form Type: 8-K
Source: 0000950170-25-107404
Chunk: 0

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-08-12
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material Definitive Agreement.

On August 6, 2025, Heron Therapeutics, Inc. (the “ Company”) entered into a Framework Agreement (the “ Framework Agreement”) with Patheon Austria GmbH & Co KG (“ Patheon”) and Thermo Fisher Scientific Inc. (solely for purposes as specified therein). Under the Framework Agreement, the Company and Patheon agreed to the terms under which Patheon will manufacture and supply the Company with specific quantities of certain products (the “ Products”) and the Company has committed to purchase 38,400 kg of Products through December 31, 2026. Patheon will continue to perform certain ongoing stability studies related to the Products and provide warehousing services. Further, the Company and Patheon terminated certain agreements previously entered into by the parties, including historical obligations thereunder, pursuant to the Framework Agreement. The Framework Agreement is subject to the additional terms of a Manufacturing and Supply Agreement previously entered into by the Company and Patheon, as amended by the amendments set forth in the Framework Agreement (the “ Amended MSA”), which governs the general terms under which Patheon will provide manufacturing services and perform stability studies related to the Products for and on behalf of the Company from time to time.

The foregoing description of the Framework Agreement does not purport to be complete and is qualified in its entirety by reference to, and should be read in conjunction with, the full text of the Framework Agreement, a copy of which the Company expects to file as an exhibit to the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                             Heron Therapeutics, Inc.                           
  Date: August 12, 2025      /s/ Ira Duarte                                     
                             Ira Duarte